799 – Efficacy of Upadacitinib As an Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis, with Or Without Previous Treatment Failure of Biologic Therapy: Data from the Dose-Ranging Phase 2B Study U-Achieve
Remo Panaccione(University of Calgary), Peter Higgins(Michigan Medicine), William J. Sandborn(University of San Diego), Fabio Cataldi(Pfizer (United States)), Geert D’Haens(Amsterdam University Medical Centers), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Wen Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bidan Huang(AbbVie (United States)), Satoshi Tanida, Subrata Ghosh, Wangang Xie(AbbVie (United States)), David Pugatch
Cited by 11
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k